The current federal picture: three different legal tracks

As of September 4, 2026, federal cannabis policy cannot be summarized accurately as either complete prohibition or nationwide legalization. Three separate tracks deserve attention:

• Hemp: The 2018 framework distinguishes qualifying hemp from marijuana under federal controlled-substance law. Congress has enacted a narrower definition, with the application of most changes now temporarily delayed. The original restrictions are explained in the Congressional Research Service hemp analysis; the September legislation changes their timing.
• Certain medical marijuana products: An April 2026 action placed covered FDA-approved marijuana products and marijuana subject to qualifying state medical marijuana licenses in Schedule III. The Justice Department announcement distinguishes this action from broader rescheduling.
• Broader marijuana rescheduling: The separate proposal to transfer marijuana more broadly to Schedule III remains in the administrative process in the official materials reviewed for this update. Follow the DEA hearing record and orders for developments.

For readers following the hemp market specifically, Green Nursery’s overview of federal hemp policy and consumer questions provides additional background. Earlier articles should be read alongside the updated dates in this guide.

A timeline of the major changes in U.S. cannabis law

These milestones explain the structure of today’s disputes. They are a national overview, rather than a record of every state enactment or court case.

The modern milestones are examined in the following sections with their governing sources. A law’s enactment date, effective date, and implementation requirements may differ.

Hemp and cannabis had American uses before prohibition

Early American hemp cultivation had practical agricultural purposes. Mount Vernon’s account of George Washington’s hemp cultivation documents industrial uses and references his farm records. That history establishes hemp’s place in American agriculture; it does not establish that historical growers used today’s intoxicating products.

Cannabis also had a medicinal history before federal prohibition. The Institute of Medicine’s historical review describes medicinal use, state restrictions, the 1937 tax law, and marijuana’s removal from the U.S. Pharmacopoeia in 1942. Historical use is evidence about the past, not a substitute for modern evidence of safety or effectiveness.

Those histories help explain why cannabis policy repeatedly returns to a basic question: should the law distinguish between agricultural uses, medical uses, and intoxication, and how should it draw those lines?

Racism and fear helped shape cannabis prohibition

Racial prejudice belongs in an accurate account of prohibition. A National Academies history describes marijuana’s association with Mexican communities and the circulation of claims that it caused insanity and violence. It also describes the role of Harry Anslinger and the Federal Bureau of Narcotics in promoting federal restrictions. Those allegations should be understood as part of the history of American narcotics policy, not repeated as established effects of cannabis.

The story also involves Black communities and cultural stigma. Richard Bonnie and Charles Whitebread’s legal history discusses cannabis use among some jazz musicians and the racial and class assumptions surrounding the response. Their historical study, reproduced in this Ohio Supreme Court resource, provides a starting point for examining how people’s identities influenced the way cannabis was portrayed.

That does not reduce every prohibition law to one motive. State drug-control systems, professional debates, federal enforcement ambitions, and sensational accounts developed over time. The University of Virginia’s summary of Bonnie and Whitebread’s research situates the 1937 law within that longer legal development.

Enforcement disparities are also part of the more recent record. The ACLU’s 2020 analysis of marijuana arrests from 2010 through 2018 found persistent racial disparities, including in states that had legalized marijuana. The organization also identified gaps in reporting; its findings describe that historical dataset, not current 2026 arrest rates.

The Controlled Substances Act and the war on drugs

Penalties had already hardened before the modern scheduling system. The Boggs Act of 1951 and Narcotic Control Act of 1956 imposed increasingly severe mandatory sentences, as documented in the National Academies history of federal drug policy. This places marijuana enforcement within a broader punitive approach to drugs.

The 1937 approach relied on taxation and registration. In 1970, the Controlled Substances Act established the scheduling system and placed marijuana in Schedule I. The Institute of Medicine account explains that transition. It is the historical starting point for today’s rescheduling dispute, although federal treatment has since changed for hemp and covered medical marijuana.

On June 17, 1971, President Richard Nixon publicly called for an intensified national and international campaign against drug abuse. His remarks preserved by the American Presidency Project addressed enforcement alongside treatment, rehabilitation, research, and education. That broader agenda helps explain the period associated with the war on drugs without confusing it with one cannabis statute.

Arguments for a different approach appeared early. The 1972 commission recommended removing criminal penalties for specified personal marijuana conduct. Richard Bonnie, who served on the commission, later explained that its members viewed the social and individual costs of criminalization as exceeding its benefits. His account of the commission’s work helps distinguish an official recommendation from the laws that governments actually adopted.

This distinction still matters. A report recommending reform, a President directing an agency to act, and a final rule with an effective date are separate events. Legal news becomes clearer when each is identified precisely.

Why a state can allow cannabis while federal restrictions remain

States have their own criminal laws and regulatory systems. California’s 1996 medical law and the 2012 adult-use measures in Colorado and Washington changed state treatment of cannabis; they did not themselves rewrite federal law. The CRS federal-state analysis explains both the limits on compelling states to enforce federal policy and the continued operation of federal controls.

The Supreme Court’s 2005 decision in Gonzales v. Raich illustrates the conflict. It upheld Congress’s power to regulate local cultivation and possession of medical marijuana even when California permitted the activity. That constitutional decision did not require Congress to maintain the same cannabis policy forever.

State permission is also specific. California’s regulator notes that cities and counties may impose local requirements and restrict cannabis businesses. Its explanation of state and local cannabis regulation shows why even a statewide legalization headline may leave important local questions unanswered.

When reading a state update, separate possession, cultivation, manufacturing, retail sales, medical access, and transportation. Permission for one activity should never be assumed to cover the others.

How the 2014 and 2018 Farm Bills created a different path for hemp

The research pathway came first

Section 7606 of the 2014 Farm Bill authorized qualifying institutions of higher education and state agriculture departments to grow industrial hemp for specified research where state law allowed it. This was a limited research framework, not an unrestricted national consumer market.

The 2018 definition changed federal controlled-substance treatment

The 2018 Farm Bill removed qualifying hemp from the federal definition of marijuana and established a national production framework. Its hemp definition used a limit of not more than 0.3% delta-9 THC on a dry-weight basis and included plant parts and derivatives. The FDA’s testimony on the 2018 Farm Bill explains both this change and the agency authority Congress preserved.

THCA and manufacturing methods complicated the discussion

THC percentage alone does not describe every regulatory requirement. USDA crop-compliance testing already accounts for the potential conversion of THCA into THC through post-decarboxylation or similarly reliable methods. The USDA laboratory guidelines therefore matter when evaluating claims that THCA was never counted before the new legislation.

The dispute over intoxicating hemp products also concerns which cannabinoids a product contains, how they were produced, and which laws govern the finished product. CRS explains how the new exclusions address these distinctions in its analysis of hemp and federal enforcement. Calling a product “hemp-derived” does not answer all of those questions.

For more detail on the measurements, continue with Green Nursery’s explanation of THC limits and hemp testing. Use this article’s September update for the revised federal timing.

McConnell’s hemp record shows the tension within reform

Mitch McConnell was a prominent supporter of hemp reform. His December 11, 2018 Senate remarks promoted the Farm Bill’s hemp provisions and their agricultural opportunities.

By November 10, 2025, he was defending new restrictions on intoxicating hemp products. In the Congressional Record, page S8129, McConnell argued that businesses had exploited the 2018 legislation and framed his proposal as protecting children and preserving the intended hemp industry. That is his stated rationale, not an independent finding about every business or product.

The distinction is useful when judging the politics. Supporting agricultural hemp does not necessarily mean supporting a national market for intoxicating hemp products. But restrictions promoted in those terms can raise broader questions about existing consumers, farmers, and businesses. The September 2026 delay demonstrates that Congress continued negotiating the consequences after enacting the restrictions.

Whether a politician is trying to preserve or reverse a legacy is an interpretation. The documented record supports a more precise question: how did the policy McConnell helped advance in 2018 relate to the restrictions he supported in 2025, and who is affected by the difference?

The new hemp definition now involves two deadlines

Section 781 of Public Law 119-37, enacted November 12, 2025, narrows the definition of hemp. Among its changes are a 0.3% total-tetrahydrocannabinols standard including THCA; exclusions involving certain manufactured cannabinoids; and a limit of 0.4 milligrams per container for the combined total of THC and other covered cannabinoids in final hemp-derived cannabinoid products. The additional cannabinoids are subject to the statutory HHS determination language. The container limit is not a per-serving allowance.

The September 2, 2026 legislation did not repeal Section 781. Its Section 2019 temporarily limits which exclusions apply. Read the dates together:

Congressman Morgan Griffith’s September 1 explanation of the legislation also identifies December 11 as the delayed date. Do not collapse the two categories into a claim that every new restriction moved, or that all hemp products are lawful until then.

The distinction between a cannabinoid that the plant cannot produce and one that can occur naturally but was manufactured outside it is especially important. Section 781 lists these separately. A product’s trade name cannot resolve its classification.

For growers, legal changes affect decisions made well before a retail sale. Green Nursery’s article on the agricultural consequences of changing hemp rules examines crop planning and buyer relationships. Its original deadline discussion predates the September delay.

Rescheduling changes controls; its scope must be read carefully

The final rule published April 28, 2026 gives that date as its effective date. It places covered FDA-approved marijuana products and marijuana subject to qualifying state medical marijuana licenses in Schedule III. It also establishes a federal registration pathway. The rule expressly leaves marijuana outside its covered categories in Schedule I.

That is a major distinction for patients, researchers, and businesses. A medical licensing pathway has a defined scope; it does not establish nationwide adult-use sales. The same rule says registrations under the new pathway do not authorize nonmedical activity.

A separate, broader rescheduling proposal has proceeded through hearings. The DEA’s regulatory action page separates the medical action from the broader process, and its hearing page provides transcripts and orders. Those records, rather than predictions about a completion date, are the appropriate place to check progress.

Three terms should remain separate: rescheduling changes a substance’s controlled-substance category; descheduling removes it from that scheduling system; and legalization describes permission for specified conduct under specified law. None should be used as shorthand for the others.

The legal debate extends beyond possession and THC limits

FDA rules govern product marketing

The 2018 Farm Bill preserved FDA authority. FDA’s cannabis and CBD guidance explains why satisfying the hemp definition does not resolve food, dietary-supplement, or drug requirements. The agency maintains that THC and CBD are excluded from the dietary-supplement definition under the applicable provisions and that adding them to food introduced into interstate commerce is prohibited under the circumstances it describes.

This is why “federally compliant hemp” and “FDA-approved product” should never be treated as equivalent claims. Green Nursery’s explanation of FDA oversight of CBD explores this distinction.

Banking, taxation, and business licenses raise separate questions

Cannabis businesses have long faced financial compliance questions beyond state licensing. FinCEN’s 2014 marijuana banking guidance established due-diligence and suspicious-activity-reporting expectations. It is part of the history of the banking problem, rather than a guarantee that a particular institution will serve a business.

Tax treatment also depends on the activity involved. The CRS analysis of the April 2026 medical marijuana action discusses Section 280E, whose deduction restriction concerns trafficking in Schedule I or II substances. Businesses should evaluate medical and adult-use activities separately rather than infer a universal tax result from rescheduling news.

Legalization does not settle every past conviction

Reform also raises questions about people already arrested or convicted. California’s official guidance on marijuana conviction relief describes automatic review and possible redesignation, dismissal, sealing, or destruction of eligible records. Eligibility and implementation matter: a headline about legalization is not confirmation that an individual record has been cleared.

Employment, housing, immigration, firearms, probation, and driving are additional subjects for focused legal coverage. Each requires its own jurisdiction-specific sources and facts. A change to cannabis possession rules should not be used to infer the answer in any of those areas.

How to evaluate the next hemp or cannabis legal headline

A useful legal update should tell you what changed and how the author knows. Before acting on a headline, work through these steps:

1. Identify the action. Is this a bill, enacted law, proposed rule, final rule, court order, or public statement?
2. Find the operative text. Read the relevant section and its definitions. A press release can help explain it, but may omit exceptions.
3. Separate the dates. Record enactment, effectiveness, compliance deadlines, and any temporary delay.
4. Identify the scope. Specify the product, cannabinoid, production method, medical or adult-use activity, and jurisdiction.
5. Check what remains unresolved. Look for required agency determinations, later amendments, and court orders affecting implementation.
6. Choose an appropriate next step. For a personal charge or business decision, take the actual documents and facts to a qualified attorney.

Product documentation can inform that review, but it should not be mistaken for a legal opinion. Likewise, a retailer’s willingness to ship is not a determination by your government. Green Nursery’s guide to CBD flower shipping questions provides a starting point for checking the different requirements involved.

Frequently asked questions about hemp and cannabis laws

Has cannabis always been illegal in the United States?

No. Agricultural hemp and medicinal cannabis uses preceded the federal prohibition framework. State restrictions developed before the 1937 federal tax law, and the 1970 Controlled Substances Act established the scheduling system discussed above.

Did racism contribute to marijuana prohibition?

Yes. The historical sources discussed above document racialized associations and fear-based claims about cannabis. Explaining that history accurately also requires distinguishing different laws, institutions, periods, and verified statements.

Did the 2018 Farm Bill legalize every hemp-derived product?

No. It changed controlled-substance treatment for qualifying hemp while preserving other legal requirements. FDA rules and applicable state restrictions still require separate analysis. FDA’s Farm Bill testimony explains that division of authority.

Was the November 2026 hemp deadline cancelled?

No. The September legislation creates a partial delay. Most changes are delayed until December 11, 2026, while the specified exclusions for products containing cannabinoids the plant cannot naturally produce remain scheduled for November 12. Read both dates in the table above.

Does the 0.4-milligram limit apply to each serving?

No. The new provision uses a combined total per container for final hemp-derived cannabinoid products, covering THC and additional cannabinoids described in the statute. It is separate from the percentage-based standard and subject to the revised implementation timing.

Is all marijuana now in Schedule III?

No. The completed medical action has a defined scope. Broader rescheduling is a separate proceeding. The DEA’s explanation of its regulatory actions is the starting point for distinguishing them.

Does a state cannabis license resolve federal requirements?

Not by itself. The activity, federal rules, and any applicable registration pathway must also be considered. A license should be read according to what it authorizes, rather than as permission for every cannabis-related activity.

Does legalization automatically erase a marijuana conviction?

There is no universal answer. Relief depends on the applicable jurisdiction, offense, dates, and procedures. Check the court record and the jurisdiction’s official relief process instead of assuming a record changed when a law passed.